1. Home
  2. VOGX

as of 09-09-2026 4:00pm EST

$29.80
$2.20
-6.87%
Stocks Health Care Biotechnology: Pharmaceutical Preparations Nasdaq

Vogenx Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for the treatment of serious diseases associated with dysfunctions in human metabolism, including post-bariatric hypoglycemia, or PBH, and gastroparesis. The company's flagship product candidate, mizagliflozin, is an orally administered, minimally absorbed, small molecule drug candidate being developed for the treatment of post-bariatric hypoglycemia (PBH), gastroparesis and GIP-induced Cushing's Syndrome. It operates as a single reportable segment engaged in the discovery and development of treatments for serious metabolic and gastrointestinal diseases.

Founded: N/A Country:
United States
United States
Employees: N/A City: N/A
Market Cap: 456.5M IPO Year: 2026
Target Price: N/A AVG Volume (30 days): 212.4K
Analyst Decision: N/A Number of Analysts: N/A
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: N/A EPS Growth: N/A
52 Week Low/High: $14.80 - $35.50 Next Earning Date: N/A
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A
P/E Ratio: N/A Index: N/A
Free Cash Flow: N/A FCF Growth: N/A

Share on Social Networks: